Other preclinical studies have revealed possible mechanisms that might explain why CSF1R blockade therapy fails, including an influx of regulatory T-cells, tumor-promoting granulocytes, TAMs resistant to CSF1R and aberrant signaling of PI3K that is downstream of CSF1R signaling [36–39] . The gene discussed is CSF1R; the disease is neoplasm.